Home World News FDA Approves Zidesamtinib for ROS1-positive Non-Small Cell Lung Cancer World News FDA Approves Zidesamtinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - September 16, 2026 99 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ARROS-1 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR How I Took Charge of My Cancer Care and Found a... August 30, 2022 Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant,... September 24, 2025 Neoadjuvant Nivolumab/Relatlimab Induces High Rates of Pathologic Responses in Patients with... November 22, 2024 First targeted treatment approved for advanced prostate cancer on NHS in... October 13, 2021 Load more HOT NEWS Marking Breast Cancer Awareness Month 2025, ESMO Calls for Increasing Awareness... EMA Recommends Extension of Indications for Dostarlimab Embracing Lung Cancer Survivorship Cervical screening in Wales extended to every 5 years: Why the...
